Critical Outcome Technologies Inc. (COTI) is a biopharmaceutical company rapidly developing targeted therapeutics, with an initial focus in oncology.
The Company’s lead program, COTI-2 for ovarian and other gynecological cancers restores normal cell signaling in cancer with p53 mutations. Our competitive advantage lies in the drug discovery process utilizing COTI’s proprietary CHEMSAS identification process. COTI is strategically positioned to build a robust internal portfolio of products, as well as help to build revenue-generating pipelines for pharmaceutical and biotechnology companies of all sizes.
- COTI-2 represents a potential breakthrough treatment for many cancers and is entering clinical trials;
- CHEMSAS, our proprietary drug discovery technology dramatically increases the odds of clinical and commercial success;
- Strong pipeline of opportunities in oncology and other therapeutic areas.
In addition to a potential breakthrough treatment for many cancers, we have a robust pipeline of optimized compounds, R&D collaborations, and other applications of our core drug discovery technology. Critical Outcome Technologies Inc. is a publicly traded company listed in Canada on the TSX Venture Exchange under the symbol COT, and in the United States on the OTCQB Venture Marketplace under the symbol COTQF.
COTI files electronically certain continuous disclosure documents on the System for Electronic Document Analysis and Retrieval (SEDAR) which can be accessed at www.sedar.com. The preceding link will open a new browser window and take you directly to the SEDAR website.